GoAI
Get started
NANO MRNA Co.,Ltd. logo

NANO MRNA Co.,Ltd.

4571.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥105

−¥3.00 · -2.78%

Aug 24, 3:30 PM JST

4571.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

NANO MRNA Co., Ltd. specializes in the discovery, advancement, and manufacturing of pharmaceutical products, employing its innovative micellar nanoparticle platform. Its biopharmaceutical pipeline is primarily geared towards addressing oncological conditions and a range of other severe illnesses. The enterprise also undertakes the full spectrum of activities for anti-cancer medications, from initial scientific investigation to market commercialization, all underpinned by its distinctive micellar nanoparticle approach. Established on June 14, 1996, by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi, the firm maintains its principal operations in Tokyo, Japan.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Shiro Akinaga
Listed since
Mar 5, 2008
Employees
23

Market position

Day range

Current ¥105

52-week range

Current ¥105

Open
¥107
Previous close
¥108
Volume
613.5K
1.11× average
Average volume
554.1K
Average daily volume
Market cap
8.73B JPY
Beta
0.38
Market reference 1
50-day average
¥101.06
+3.90% above average
200-day average
¥135.24
-22.36% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
7.74B JPY
P/E (TTM)
-7.81×
P/B (TTM)
2.63×
P/S (TTM)
43.14×
EV / EBITDA
-8.67×
Earnings yield
-8.55%
Free cash flow yield
0.00%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
88.83%
Operating margin
-519.56%
Net margin
-505.92%
Return on equity
-26.47%
Return on assets
-15.98%
Return on invested capital
-18.50%

Financial health

Debt / equity
0.36×
Current ratio
5.28×
Altman Z-score
1.97
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends175%-173%-520%-867%Gross margin, FY2021: 83.66%Gross margin, FY2022: 78.94%Gross margin, FY2023: 81.88%Gross margin, FY2024: 72.03%Gross margin, FY2025: 87.85%Operating margin, FY2021: -780.62%Operating margin, FY2022: -616.26%Operating margin, FY2023: -637.91%Operating margin, FY2024: -696.07%Operating margin, FY2025: -553.58%Net margin, FY2021: -712.67%Net margin, FY2022: -648.39%Net margin, FY2023: -575.61%Net margin, FY2024: -769.82%Net margin, FY2025: -540.91%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 83.66%. Gross margin FY2022 78.94%. Gross margin FY2023 81.88%. Gross margin FY2024 72.03%. Gross margin FY2025 87.85%. Operating margin FY2021 -780.62%. Operating margin FY2022 -616.26%. Operating margin FY2023 -637.91%. Operating margin FY2024 -696.07%. Operating margin FY2025 -553.58%. Net margin FY2021 -712.67%. Net margin FY2022 -648.39%. Net margin FY2023 -575.61%. Net margin FY2024 -769.82%. Net margin FY2025 -540.91%.

Income trends

Revenue

174.5M JPY+60.80%

Operating income

−965.99M JPY-27.89%

Net income

−943.88M JPY-12.99%
Income trends across reported periods496.54M JPY−433.5M JPY−1.36B JPY−2.29B JPYRevenue, FY2021: 264.03M JPYRevenue, FY2022: 202.19M JPYRevenue, FY2023: 135.51M JPYRevenue, FY2024: 108.52M JPYRevenue, FY2025: 174.5M JPYOperating income, FY2021: −2.06B JPYOperating income, FY2022: −1.25B JPYOperating income, FY2023: −864.42M JPYOperating income, FY2024: −755.35M JPYOperating income, FY2025: −965.99M JPYNet income, FY2021: −1.88B JPYNet income, FY2022: −1.31B JPYNet income, FY2023: −780M JPYNet income, FY2024: −835.38M JPYNet income, FY2025: −943.88M JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 264.03M JPY. Revenue FY2022 202.19M JPY. Revenue FY2023 135.51M JPY. Revenue FY2024 108.52M JPY. Revenue FY2025 174.5M JPY. Operating income FY2021 −2.06B JPY. Operating income FY2022 −1.25B JPY. Operating income FY2023 −864.42M JPY. Operating income FY2024 −755.35M JPY. Operating income FY2025 −965.99M JPY. Net income FY2021 −1.88B JPY. Net income FY2022 −1.31B JPY. Net income FY2023 −780M JPY. Net income FY2024 −835.38M JPY. Net income FY2025 −943.88M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue174.5M JPY108.52M JPY135.51M JPY202.19M JPY264.03M JPY
Cost of goods sold21.2M JPY30.35M JPY24.55M JPY42.59M JPY43.15M JPY
Gross profit153.3M JPY78.17M JPY110.96M JPY159.6M JPY220.88M JPY
Research and development—422.48M JPY647.4M JPY1.12B JPY1.92B JPY
Selling, general, and administrative1.12B JPY411.03M JPY327.97M JPY284.7M JPY287.94M JPY
Operating expenses1.12B JPY833.52M JPY975.37M JPY1.41B JPY2.28B JPY
Interest income33.08M JPY31.31M JPY26.18M JPY25.37M JPY12.84M JPY
Interest expense48.14M JPY——5.67M JPY1.78M JPY
Depreciation and amortization497K JPY22K JPY1.1M JPY136K JPY4.49M JPY
Operating income−965.99M JPY−755.35M JPY−864.42M JPY−1.25B JPY−2.06B JPY
Net income−943.88M JPY−835.38M JPY−780M JPY−1.31B JPY−1.88B JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-3.39

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.93-2.44-3.95-5.46Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 14, 2024: actual -5.14, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 14, 2025: actual -1.09, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual -3.4, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 8, 2025: actual -2.85, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual -3.35, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual -2.86, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual -3.84, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 7, 2026: actual -3.39, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates95.56M65.69M35.82M5.95MQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 14, 2024: actual 7.7M JPY, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 14, 2025: actual 76M JPY, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual 25M JPY, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 8, 2025: actual 7M JPY, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual 34M JPY, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual 89M JPY, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual 44M JPY, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 7, 2026: actual 35M JPY, estimate —, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Mar 27, 2014

100:1

Stock split

Effective Oct 22, 2010

12:11

4571.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,987

-0.34%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,797

+0.57%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,895

0.00%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,210

+0.12%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,858

+0.86%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,406.5

+0.82%

Continue in GoAI

Research 4571.T

research.disclaimer